Hong Kong stock movement: AKESO fell 11.52%, with increased uncertainty in clinical data and strong market wait-and-see sentiment

Hong Kong Stock Movement Akeso fell 11.52%. Based on recent key news: On April 21, the American Society of Clinical Oncology announced that clinical project abstracts to be reported at the annual meeting from May 29 to June 2 will include overall survival data from the HARMONi-6 clinical trial. Despite repeated inquiries from market participants, the company has not formally disclosed relevant information, leading to increased market uncertainty and a decline in stock price. Source: Nomura Securities On April 23, Nomura Securities raised Akeso's target price by 27% to HKD 142.75, maintaining a "Neutral" rating. Despite the target price increase, the rating remains unchanged, and the market continues to adopt a wait-and-see attitude towards the company's future performance, affecting the stock price. Source: Nomura Securities No other significant news recently. The impact of industry clinical trial data is significant. Stocks with High Trading Volume in the Industry 3SBio fell 12.73%. Based on recent key news: On April 20, Zhitong Finance reported that the MSCI China Healthcare Index rose 12.3%, outperforming the MSCI China Index by 13.6%. The Chinese government work report lists biomedicine as an emerging pillar industry, with policy catalysts restoring risk appetite in the sector. 3SBio is recommended as a buy, with a target price of HKD 34.87. On April 20, Huigang Communications pointed out that breakthroughs in AI pharmaceutical technology and the internationalization of Chinese innovative drugs are creating a dual resonance, accelerating the improvement of the industry's fundamentals. 3SBio is listed as a key recommendation, with a target price of HKD 34.87. On April 20, CMB International emphasized the transformation of the pharmaceutical industry into an emerging pillar industry, with policy dividends continuing to be released. 3SBio received a buy rating, with a target price of HKD 34.87. The pharmaceutical sector is experiencing the release of policy dividends, restoring risk appetite. Innovent Biologics fell 5.33%. Based on recent news: On April 21, JP Morgan included Innovent Biologics in its latest preferred list and gave it an "Overweight" rating, with a target price of HKD 111. Despite the positive rating, the market reaction was poor, leading to a decline in stock price. On April 20, CMB International released a report stating that the MSCI China Healthcare Index has cumulatively risen 12.3% since the beginning of 2026, but Innovent Biologics has failed to follow the overall sector's rise and has instead seen a pullback. On April 20, Huigang Communications reported that the Chinese government work report lists biomedicine as an emerging pillar industry. Despite favorable policies, Innovent Biologics' stock price still fell, indicating market skepticism about its short-term performance. The valuation repair window for the innovative drug sector is emerging, and market liquidity concerns are easing. Rongchang Biologics fell 7.12%, with a trading volume of HKD 431 million, and no significant news recently. The trading is active, with clear capital flow. Considering the sector and industry trends, this stock shows significant volatility, and specific reasons need further observation Stocks Ranked Among the Top by Industry Market Value BeiGene fell 1.82%. Based on recent key news: On April 21, the valuation of the Hong Kong stock market's innovative drug sector fell to a historically low level, prompting a reconstruction of the investment logic for the innovative drug sector. BeiGene, as the first international innovative pharmaceutical company to achieve profitability, has attracted market attention. Data source: Wind On April 22, the financial report of Heng Rui Medicine showed that its innovative drug revenue accounted for more than half, but the market questioned the sustainability of its profitability, affecting the overall market sentiment of the innovative drug sector. Data source: Jiemian News On April 21, the innovative drug sector is sensitive to liquidity conditions. As market liquidity concerns eased, the sector welcomed a valuation repair window, and BeiGene, as one of the leading companies, was affected by market fluctuations. Data source: Wind The valuation repair window for the innovative drug sector has emerged